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Abstract
Echinococcosis or hydatid disease is a near-cosmopolitan parasitic zoonosis caused
by the larval stages of cestodes of the genus Echinococcus, whose spectrum of clinical
manifestations can vary from asymptomatic infection to death, the liver being the most
frequently affected organ. In the absence of an adequate treatment, case fatality rate
of affected patients may reach 100%, so clinical suspicion should always be accom‐
panied by a complete workup and a prompt treatment. Like other zoonotic parasitic
diseases, echinococcosis is associated with low socioeconomic and cultural levels,
especially affecting rural areas of developing countries, not only by the morbidity and
mortality it produces, but also by the economic impact associated to health care costs
and productivity losses. Despite this, in Colombia and in other South American
countries, epidemiological studies of this disease are limited, so it is not known with
certainty the incidence, the prevalence, and the burden of the disease. The objective
of this chapter is to summarize and describe epidemiological and clinical updated
aspects of the disease, focusing on evidences and published research articles on
echinococcosis in Colombia, finally questioning if this cestode zoonotic disease has
been largely neglected.
Keywords: Echinococcosis, Echinococcus, Colombia, neglected diseases, zoonotic in‐
fectious diseases
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1. Introduction
Echinococcosis or hydatid disease is a near-cosmopolitan parasitic zoonosis caused by the
larval stages (paratenic for humans) of cestodes of the genus Echinococcus (Figure 1) [1, 2]. This
helminthiasis causes an important economic loss over agricultural and pastoral regions of
limited resources, particularly in developing countries [3]. In addition, it is also important to
notice that this is one of the important infectious disease groups caused by larval stages of
cestodes, which also include cysticercosis (caused by larval stages of Taenia solium), coenuriasis
(caused by larval stages of Taenia multiceps gaigeri), and sparganosis (caused by larval stages
of Spirometra), among others.
Biologically and taxonomically, although in the past it was considered as part of the genus
Taenia, Echinococcus genus belongs to the family Taeniidae (order Cyclophyllidea, subclass
Eucestoda, class Cestoda, phylum Platyhelminthes). Family Taeniidae also includes the genus
Taenia. Order Cyclophyllidea has two important families that infect humans: Hymenolepidi‐
dae (Hymenolepis) and Dipylidiidae (Dipylidium). Subclass Eucestoda includes the order Diphyl‐
lobothriidea that belongs to family Diphyllobothriidae and genus Diphyllobothrium.
Although, 12 species have been recognized, only four are of public health concern and produce
human pathology: Echinococcus granulosus (cystic echinococcosis), E. multilocularis (alveolar
echinococcosis), E. vogeli, and E. oligarthrus (both causing polycystic echinococcosis). The first
two species are etiological agents of life-threatening diseases, having high fatality rate and
poor prognosis if careful clinical management is not given [2]. E. vogeli and E. oligarthrus are
responsible for polycystic echinococcosis in Central and South America [2]. Majority of the
cases reported in these regions, till 2008, have corresponded to E. vogeli (54 of 172; 31.4%) and
E. cf. vogeli (confer, species affinis) (114 of 172; 66.3%) [3]. Only three cases (1.7%) have been
identified that have corresponded to E. oligarthrus and one has corresponded to E. granulosus
(0.6%) [3]. In the past, it was believed that E. multilocularis was not present in Central and South
America.
Living or having lived in rural areas where farming and animal husbandry are common is an
important risk factor for this disease, in some areas particularly where people frequently come
in contact with dogs that accompany paca hunters as well as where wild animal hunting for
food is common practice (e.g., hunters and aboriginal people) [4]. In addition, new population
migration patterns over the past four decades have caused a change in the profile of this
disease, allowing its worldwide distribution [4]. In addition, in general, now it is considered
that there is a risk of getting echinococcosis infection, as well other cestodiasis, while traveling
to endemic zones.
This disease is related with extensive livestock or poor health infrastructures; usually associ‐
ated with a low socioeconomic level and lack of education. Its public health importance is
related not only to the high fatality rate in humans but also with reduced work performance,
costs of hospitalization, interventions, and disabilities [5].
Although echinococcosis has been recognized for centuries (at the 17th century, Francesco Redi
illustrated that the hydatid cysts of echinococcosis were of “animal” origin), in some countries
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of the neotropic region, such as Colombia, this disease was discovered during 20th century).
Studies in this context in this country, as well as in other countries of South America, are still
limited. Therefore, the objective of this chapter is to summarize and describe epidemiological
and clinical updated aspects of this disease, focusing on evidences and published research
articles on echinococcosis in Colombia, finally questioning if this cestode zoonotic disease has










































Figure 1. Scolex and hooks of Echinococcus granulosus (pictures by A. J. Rodriguez-Morales).
2. Organisms causing human disease
2.1. Echinococcus granulosus
(Cystic echinococcosis)
E. granulosus is a cestode whose life cycle involves dogs (Canis lupus familiaris) and other canids
(coyote, dingo, red fox, among others) as definitive hosts for the intestinal tapeworm, which
are infected by ingestion of food containing hydatid cysts with viable protoscoleces, and
domestic and wild ungulates as intermediate hosts for the tissue invading metacestode (larval)
stage (Figure 1) [1]. The metacestode (or hydatid cyst) consists of two parasite-derived layers:
an inner nucleated germinal layer, and an outer acellular laminated layer surrounded by a
host-derived fibrous capsule [2]. Intermediate host species depends on the infecting strain of
E. granulosus, regional or local differences in the availability of the various intermediate host
species, and other factors [2], but would include primarily ungulates, also marsupials [which
for the case of Colombia would make think the possibility of occurrence in the country given
the wide presence of them, such as Didelphis marsupialis (locally called “chucha”)]. Ten strains
of E. granulosus have been identified so far (G1–G10) with different host affinities: G1–G2 being
sheep strains, G3 and G5 bovid strains, G4 a horse strain, G6 a camelid strain, G7 a pig strain,
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G8 a cervid strain, G9 has been described in swine in Poland, and G10 in reindeer in Eurasia
[1, 81]. The sheep strain (G1) is most commonly associated with human infections [1]. The
presence of diverse strains of E. granulosus has important implications for public health. The
shortened maturation time of the adult form of the parasite in the intestine of dogs suggests
that the interval period for administering anti-parasite drugs to infected dogs will have to be
shortened in those areas where the G2, G5, and G6 strains are found [1]. The adult E. granulo‐
sus is 2.0 to 7.0 mm in length. It has three proglottids (range 4–6). It is supposed that E.
granulosus is found worldwide; however, in many countries (including Colombia and other
countries in South America), its presence has not been confirmed both in humans and in
animals. Hydatid cysts are predominantly found in liver and lungs (Figure 1).
2.2. Echinococcus multilocularis
(Alveolar echinococcosis)
E. multilocularis is the etiological agent of the alveolar echinococcosis, its infection is perpetu‐
ated in a sylvatic cycle, with wild carnivores—mainly red (Vulpes vulpes) and arctic (Alopex
lagopis) foxes—regarded as the most important definitive hosts. Domestic dogs and cats may
be involved in a synanthropic cycle, and also raccoon dog and coyotes [2]. Small mammals
(usually microtine and arvicolid rodents) act as intermediate hosts. The metacestode of E.
multilocularis is a tumor-like, infiltrating structure consisting of many small vesicles embedded
in stroma of connective tissue. The metacestode mass usually contains a semisolid matrix
rather than fluid. The adult tapeworm is different in size than adult E. granulosus (1.2–4.5 mm)
and its eggs are indistinguishable by light microscopy. The hydatid cysts do not form hyaline
membrane and the scolices, which are abundant in rodents but absent in humans. People
become exposed to E. multilocularis by handling of infected hosts, or by ingestion of food
contaminated with eggs of the parasite [2].
It is endemic in North America, Alaska, Europe, Central Russia, China, Turkey, Japan,
Uruguay, and Argentina. In humans, the most frequently affected organs are the liver (80%),
lungs (10%), brain (5%), and other organs such as kidney and pancreas (5%) [6]. E. multilocu‐
laris has five proglottids (range 2–6). Hydatid cysts are primarily hepatic, with metastases in
lungs, brain, and bones among other organs.
2.3. Echinococcus oligarthrus
(Polycystic echinococcosis)
E. oligarthrus is the smallest species of the genus, it only measures, in its adult form, 2.2 to 2.9
mm. Definitive hosts are different species of wild felidae (pampas cats, Geoffrey’s cat, ocelot,
jaguar, cougar, jaguarandi, puma, boat cats) and intermediate hosts are rodents like rats (spiny
rat), agoutis, and pacas (both, very highly distributed in the whole territory of Colombia and
in most of the tropical areas of South America, including Brazil, Paraguay, Bolivia, Peru,
Ecuador, Venezuela, Guyana, Suriname, and French Guyana) [6]. Hydatid cysts are located in
an extrahepatic location, mostly in the intermuscular tissue, pleural, and peritoneal cavity [6].
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E. vogeli also causes polycystic echinococcosis and has been reported only in Central and South
America. However, not every country in this region has reported cases of E. vogeli. Brazil (98
cases) and Colombia (30 cases) have been the countries with the highest number of reported
cases, till 2010 (including E. cf. vogeli) [6]. The adult tapeworm measures 5.6 mm. The eggs are
similar to that of the Taenia genus. Definitive hosts are domestic and wild dogs (bush dog and
domestic dog). The bush dog, Speothos venaticus, is widely distributed in South America,
particularly not only in Brazil (>80% of the territory) but also in most parts of Venezuela,
Guyana, Suriname, and French Guyana, as well as in some areas of Colombia, Panama,
Ecuador, Peru, Paraguay, Argentina, and Uruguay. Intermediate hosts are rodents, but mainly
the agoutis and pacas. In this species, the hydatid cyst is of endogenous proliferation and it
forms bags or folds inside the primary bladder [6]. While in rodent the larvae is limited, in
humans it disseminates, due to exogenous vesiculation and due to the amount of scolice inside
the cyst, which can cause reinfection when it breaks spontaneously or by medical manipulation
[6]. The adult E. vogeli is 3.9 to 5.6 mm in length. E. vogeli has three proglottids.
The results of a survey (carried out to detect Echinococcus infections) involving more than 4,000
Colombian mammals showed interesting findings regarding E. vogeli and E. oligarthrus. Adult
worms were found in 5 of 121 carnivores: E. oligarthrus in 1 of 11 ocelots, 2 of 9 jaguarundi cats,
and single puma; and E. vogeli in 1 of 15 domestic dogs. Although bush dogs were present,
none could be examined. Polycystic larvae were found in 96 of 325 pacas (29.5%) and in 6 of
1,168 (0.5%) spiny rats, Proechimys spp. None of the 118 agouti showed hydatid cysts but an
infected heart was provided by hunters. The paca’s infection rate increased with age but was
not related to gender or geographic region. In 73 of 96 pacas, the infection was due to E.
vogeli, and the cysts were located in the liver. In three cases, it was due to E. oligarthrus and the
hydatid cysts were extrahepatic, mainly attached to muscles. In the remaining 20, the species
involved could not be determined. The parasites in two of the spiny rats, and in the agouti
heart were E. oligarthrus [48]. Although most of the infected animals were collected in the
eastern plains, other records and verbal information indicate that, at least in Colombia where
man has not exterminated pacas, agoutis, wild canids, and felids, one still can find enzootic
neotropical Echinococcus infection. The cycle of E. vogeli involves the bush dog and paca as
hosts, and that of E. oligarthrus, the paca, agouti, spiny rat, and several species of wild felids [48].
Other species in the genus Echinococcus have also been discovered and identified. Currently,
there are 12 species, including those four causing human pathology, six identified in animals:
E. canadensis (main intermediate host: cervids; known definite hosts: wolves, dog), E. equinus
(main intermediate host: horses; known definite host: dogs), E. felidis (main intermediate host:
warthogs; known definite host: lions), E. intermedius (main intermediate hosts: camels, pigs,
sheep; known definite hosts lions), E. ortleppi (main intermediate host: cattle; known definite
hosts dogs), and E. shiquicus (main intermediate host: pika; known definite host: Tibetan fox);
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and two to be assigned to name species (Echinococcus sp. GL-2010 and Echinococcus sp. GL-2012)
(http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=6209) [46].
Some  authors  have  recently  exposed  that  all  these  species  would  be  infectious  for  hu‐
mans, probably with the exception of E. equinus, E. felidis, and E. shiquicus, and also the two
to be assigned to name species [46]. Probably, with more studies in molecular epidemiolo‐
gy in the future, their role will become clear.. However, it is interesting to note that at the
GenBank  (http://www.ncbi.nlm.nih.gov/gene/?term=echinococcus),  there  are  271  genes
identified from different species of Echinococcus: E. oligarthrus (36 genes), E. vogeli (36 genes),
E. shiquicus (36 genes), E. canadensis  (36 genes), E. equinus (36  genes), E. felidis (36 genes),
E.  ortleppi  (14  genes),  E.  multilocularis  (12  genes),  and E.  granulosus  (12  genes).  At  Gen‐
Bank,  there  are  also  43,971  sequences  of  proteins  of  the  genus  Echinococcus  (http://
www.ncbi.nlm.nih.gov/protein/?term=echinococcus):  E.  granulosus  (24,310  sequences),  E.
multilocularis  (18,670  sequences),  E.  canadensis  (476  sequences),  E.  shiquicus  (111  sequen‐
ces),  E.  equinus  (77  sequences),  E.  ortleppi  (66  sequences),  E.  vogeli  (51  sequences),  E.
oligarthrus (47 sequences), and E. felidis (34 sequences).
More importantly, a draft genomic sequence for E. granulosus comprising 151.6 Mb encoding
11,325 genes has been achieved [47], including the evaluation of the regulation of genes in the
adult, oncosphere, hydatid cyst, and protoscoleces, which would be of great significance for
further studies in diagnostic as well in the immunology and vaccine development, among
other things.
3. Life cycle
The adult E. granulosus lives in the small intestine of the definitive hosts (dogs or other canids)
(Figure 2). Gravid proglottids release eggs that are passed in the feces of these animals (which
would come in close contact with humans). After ingestion by a suitable intermediate host
(sheep, goat, swine, cattle, horses, camel, under usual natural conditions), embryonated eggs
are hatched in the small intestine of the intermediate host and release the oncosphere which
penetrates the intestinal wall and migrates through the circulatory system into various organs,
especially the liver and lungs (Figure 2).
In these organs, the oncosphere develops into a cyst that enlarges gradually, producing
protoscolices and daughter cysts that fill the cyst interior (Figure 2). The definitive host
becomes infected by ingesting the cyst-containing organs of the infected intermediate host
(Figure 2). After ingestion, the protoscolices evaginate, attach to the intestinal mucosa, and
develop into adult stages in approximately 32 to 80 days (Figure 2). Humans can also get
infected by ingesting eggs from feces of definitive hosts infected, then resulting with the release
of oncospheres in the intestine and the development of cysts in different organs (mainly liver
and lungs) (Figure 2).
The same life cycle occurs with E. multilocularis, E. vogeli, and E. oligarthrus, with the differences
in the definitive or main hosts and the intermediate hosts involved for these species (Figure 2).
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4. Geographical distribution
Cystic echinococcosis or cystic hydatidosis (caused by E. granulosus) is an important public
health problem in South America, the Middle East and Eastern Mediterranean, some sub-
Saharan African countries, China, the former Soviet Union, Russia, and the new related
countries (Figure 3) [7, 8]. The overall prevalence of echinococcal infection is underestimated
in many countries because systematic population surveys are not performed in all endemic
areas, and this disease is not under surveillance neither in humans nor in animals in most of
these countries [9]. Even more, in some countries, such as Colombia, there are reports from
animal health authorities claiming that echinococcosis as a disease has “never” been registered
in the country [49]. In endemic areas, its incidence has been estimated to be around 50 cases
per 100,000 population per year [10].
In South America, although there is underreporting, it has been estimated that each year there
would be occurring 2,000 cases [3], but these are not the exact figures. Uruguay has reported
9.2 cases per 100,000 population in 1995, and Chile has reported between 6.6 and 8.4 new cases
per 100,000 population per year. Besides this, echinococcosis is also a health problem in
Argentina, Bolivia, Brazil, and Peru [10, 82]. In the Peruvian Andes, observed prevalence rates
in one study among humans, canines, and sheep were 9%, 46%, and 32%, respectively [9].
World Health Organization (WHO) had developed a global map of the distribution of E.
granulosus and cystic echinococcosis (hydatidosis, 2009); however, there is no recent official
WHO map for distribution of other Echinococcus species (Figure 3) [50]. However, in 2001,
WHO and World Organization for Animal Health also developed a map of the approxi‐
Figure 2. Life cycle of echinococcosis (pictures by A. J. Rodriguez-Morales).
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mate geographical distribution of E. multilocularis and alveolar echinococcosis (1999) (Figure
4) [51, 52].
E. multilocularis is limited to the northern hemisphere (Figure 4). It occurs in Central and
Eastern Europe, the former Soviet Union (now Russia), Turkey, Iraq, northern India, central
China, some Japanese islands, some provinces of Canada, Alaska, and some north central states
of the United States [9] (Figure 4).
Distribution of E. oligarthrus and E. vogeli is limited to South and Central America, but there is
no precise map regarding their presence in the countries of these regions.
Since definitive host of E. vogeli exists only from Panama to the North of Argentina, cases of
polycystic hydatidosis outside of this region of the world are probably imported by E.
oligarthrus [9]. However, there are no precise estimations of E. oligarthrus. An attempt to map
the distribution of E. vogeli was presented in 2005 by Colombian authors (Figure 5).
Normally, infections from species of the genus Echinococcus involve wild and rural hosts;
however, due to human actions (temporary by recreation and work, but also definitive) which
have permanently used dogs in work grazing and fed them with viscera of sacrificed animals,
this cycle has been altered [6]. Since all types of echinococcosis or hydatidosis are acquired by
ingestion of water or food contaminated with the eggs in the feces shed by the carnivores, it
Figure 3. Distribution of Echinococcus granulosus and cystic echinococcosis (hydatidosis), 2009 (2010) [50].
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Figure 4. Approximate geographical distribution of Echinococcus multilocularis and alveolar echinococcosis (1999) [51,
52].
Figure 5. Drawing illustrates the geographic distribution of hydatid disease from Echinococcus granulosus (red dots), E.
multilocularis (black dots), and E. vogeli (green dots). E. granulosus is the most common of the Echinococcus species (1999)
[53]. This is not precise and requires more specific information from the countries regarding the distribution of cases
by the territories included in the map.
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is advisable to take special care with the feces of these animals, especially when considering
that these eggs resist partial desiccation for several months [6].
5. Echinococcosis studies in Colombia
In Colombia, echinococcosis does not seem to be a major problem if we base such assumptions
from human and animal health authorities [49]. But, as has been evidenced, cases of infection
with the larval forms of E. granulosus have been reported [11]. However, prevalence and
incidence of this entity have not been determined. Echinococcosis is not under surveillance
and there is no obligation to report cases related to this infection to health authorities in the
country; then known cases have been just those reported in national and international
biomedical literature (Figure 6).
Figure 6. Departments of Colombia where cases of echinococcosis have been reported. (First date reported is the year
of the case, then the location, year of publication in parenthesis, and main author.)
The first case was reported in 1941 [12], but since 1957, more cases had been reported [54]
(Figure 6). Two decades later, D’Alessandro began studies in the country. This author found
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more than a dozen of human cases of polycystic echinococcosis produced by the larval stage
of E. vogeli whose definitive hosts were wild and domestic dogs and intermediate host was
paca (“guagua,” Cuniculus paca) [3, 55], after suspecting the presence of disease due to four
cases of calcified hydatid cysts [55].
Most of the infected people were native from Colombia who acquired the disease by ingesting
food or water contaminated with dog feces and by eating raw viscera of “guagua.” Botero et
al. describe three more unpublished cases: two from the coast of the Pacific Ocean and one
from Santa Marta [13, 14]. D’Alessandro’s studies demonstrated that in Colombia, the guagua
is the main intermediate host and the wild dogs known as gouache fox is the definitive host.
The guatin, which is also an edible animal for Colombian indigenous tribes, is a more specific
host for E. oligarthrus [6].
Till 2008, the country in South America with the highest number of cases reported was Brazil,
with 99 cases, followed by Colombia with 29 (Figure 6) [3, 50-60]. In Colombia, some authors
believe that there are more cases not reported, in fact due to the lack of records. This also probes
that occurrence of echinococcosis is more evidently reported, when people in the rural and
jungle areas receive health services and physicians are more aware of the disease [60].
Two years later, in 2010, another and the last case till March 2015, has been reported [61]. A
case of cardiac echinococcosis, detected in echocardiographic finding in an 18-year-old woman
diagnosed in Medellin, Antioquia [61]. Fortunately in this case, physicians suspected of this
cestode infection; however, more awareness among physicians regarding the compromise of
cardiovascular system in many parasitic diseases is still necessary, particularly in endemic
areas [63-67].
Based on this review of cases, including information from the departments of the country
where this disease has been reported, a map for Colombia has been proposed (Figure 6). This
map shows the departments of the country (including locations of origin of one or more cases),
where echinococcosis have been reported (Figure 6). At least 10 departments (out of 32 in total)
have reported cases of echinococcosis (Figure 6) [14, 54, 59-61, 72].
Beyond this, with an increasing number of published reports concerning this disease, medical
personnel in tropical areas, as in Colombia and more recently in Brazil, have been keenly
interested in undertaking epidemiological surveys [3, 68, 69]. Even more, there is a significant
zoonotic potential, given the fact that the investigations in Colombia demonstrated a large
enzootic areas of transmission in the oriental plains of that country [3, 58], where multiple
species and a high number of animals have been found positive in the evaluations for
Echinococcus, particularly E. oligarthrus.
As in other zoonotic diseases, parasitic and of other etiologies, there is a clear need of more
studies, as well as more interaction between physicians and veterinarians. More research is
necessary; currently, there are just 10 reports available in Medline for Colombia (using the
terms “Colombia” AND “Echinococc*” [means Echinococcus and/or echinococcosis]) [53, 55-60,
62, 70, 71]. There is no significantly different information available at Scopus. At SciELO, there
is one additional case, a patient with hepatic hydatidosis who appeared as an eosinophilic
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pleural effusion serologically confirmed, treated with combined therapy with albendazole and
the percutaneous aspiration-injection-reaspiration drainage technique [72].
Finally, an undergoing research of our group is analyzing a new source of information for
communicable diseases, which are not under surveillance and require compulsory notifica‐
tion. In Colombia, there is a service, which is now available for analyses, the so-called personal
health records (Registro Individual de Prestación de Servicios, RIPS), where diagnoses are
classified according to WHO cause groups International Classification of Diseases version 10
(ICD-10). At this system, we retrieved the cases of echinococcosis between years 2009 and 2013,
finding 303 cases (Figure 7).
Figure 7. Cases of echinococcosis (ICD-10 codes B67.0 to B67.9) reported to the personal health records of Colombia
(RIPS) during 2009–2013.
Although these cases corresponded in 18.2% to “Echinococcosis, unspecified, of liver” (B67.8)
and 21.5% to “Echinococcosis, other and unspecified” (B67.9), there are 60.4% (n = 183) of them
classified as infection due to E. granulosus (47.5%) and E. multilocularis (12.9%) in different
organs (Figure 7), mainly lung for E. granulosus (17.8%) (Figure 7). Although there are limita‐
tions to this source, there is useful information that should be further analyzed. Epidemiolog‐
ical factors (geographic distribution, age groups, gender) involved in these cases would be of
high interest in describing the situation of echinococcosis in the country.
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In these cases, looked retrospectively, the limitation in the approach is that there is no
information regarding the diagnostic techniques implemented in each case, and how these
cases were therapeutically managed. Then, based on this information, cross-sectional and
prospective studies should be implemented in the countries, and there should also be an
increase in the awareness about the existence and occurrence of such diseases in different areas
of the country, and particularly in those that had previously reported case reports and case
series since early decades (Figure 6).
6. Economic burden of echinococcosis
According to the World Bank, economic losses due to this disease stand at the fourth position
after other diseases and trauma [3].
Echinococcosis also affects the economy of the endemic regions. In humans, losses are due to
costs of hospitalization, treatment, disability, etc. However, in livestock, losses are due to lost
productivity, losses in quality of the wool and meat, and decreased milk production and
fertility [15]. Estimated annual economic losses in Peru are $ 178,705 [10]. In Colombia,
estimation of the economic burden of this disease has not been reported, but given the increase
in the number of economic evaluations of infectious diseases in the country and in the region
[73, 74], there would be more clear details once the number of cases reported would be defined.
7. Clinical manifestations
Regardless of the etiology, a new concept of organ compromise was proposed in 2014, when
two or more organs are affected by echinococcosis at the same time in a patient. This has been
defined as multivisceral echinococcosis, simultaneous localization of hydatid cysts in more
than one organ [83]. Multivisceral echinococcosis should be differentiated from multiple
echinococcosis [83]. The latter is the localization of multiple cysts in one organ [83]. Even in
paired organs (lungs, kidneys) if both are compromised, it will be a case of multivisceral
echinococcosis, given the implications not just in diagnosis, but particularly in surgical
management.
7.1. Echinococcus granulosus
Echinococcosis is a larval infection caused in humans by Echinococcus species, a metacestode
with the ability to create a large spectrum of clinical manifestations, including the asympto‐
matic infection, and a severe and fatal disease. There are four species of echinococcosis that
have been recognized that cause various forms of the disease, specifically the E. granulosus
species which is responsible for cystic echinococcosis [16].




As a general rule, the phase of primary infection is always asymptomatic because the cysts are
located in different organs, characterized by their small size, which is less than 5 cm and are
encapsulated. This first phase is not been associated with major pathology and might remain
asymptomatic for a long period or permanently [16, 17]. The incubation period is undefined
but it could be in around months or even years, before the infection becomes symptomatic.
There have been reported cases of spontaneous cure due to cyst calcification and collapse and
on the other hand, there are cases of early symptomatology because of cyst rupture [16, 18].
7.1.2. Patient characteristics
Cystic echinococcosis is seen in all ages, including patients aged below 1 year and above 75
years, with a majority between 6 and 15 years, 21 and 30, and 30 and 40 years. The most risky
profession involves farm labors [16].
7.1.3. Symptoms
There is a huge spectrum of clinical manifestations that are variable among the patients and
none of these are considered as pathognomonic of echinococcosis [16]. All the symptoms might
depend on different characteristics such as the host-parasite interaction, the different organs
involved, cyst size, and the presence of different complications such as cyst rupture or trauma
[16, 18]. The most commonly compromised organs are the liver, followed by lung, kidney,
spleen, and less common organs like muscles, skin, abdominal cavity, and pelvic cavity. The
symptoms may vary in accordance with the organ involved [16-18].
Liver infections include symptoms such as hepatomegaly, cholecystitis, jaundice, liver abscess,
or secondary biliary cirrhosis. Lung infections include symptoms like chest pain, expectora‐
tion, hemoptysis, and dyspnea [19]. Other severe manifestations include cyst getting rupture
into biliary tree causing biliary colic, jaundice and can be confused with pancreatitis or
cholangitis [16, 19].
7.1.4. Liver involvement
The liver is the most commonly involved organ, representing around two-thirds of the cases.
The right lobe is compromised in the majority of the cases (60% to 80%) but it frequently does
not produce symptoms and when these once occur, it is estimated that the cyst size is around
10 cm [20, 21]. Once a cyst develops a larger size, hepatomegaly might occur and other
symptoms like right upper quadrant pain, nausea, and vomiting can also result. Due to the
mass defect of the cyst compression of the portal and hepatic veins, it can result in Budd-Chiari
syndrome [19, 20].
7.1.5. Lung involvement
The most common symptom of lung infection is the presence of cough in around 53% to 62%
of the patients, followed by chest pain, dyspnea, and hemoptysis. But generally, most of the
patients with lung infection are asymptomatic [21, 22].
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7.1.6. Other organs
Heart infection might generate rupture with pericardial tamponade, cardiac insufficiency,
embolism or pericardial effusion [23-25, 60, 64, 66]. The central nervous system can lead to
seizures or symptoms due to an increase in the intracranial pressure [26]. Kidney disease can
cause hematuria, and even glomerulonephritis and nephrotic syndrome have been described.
Bones are mostly asymptomatic and only develop manifestations when a pathological fracture
occurs [23].
7.1.7. Outcome
Surgeries are performed in around 15% of the patients after the initial diagnosis. And in
patients without surgery, majority would remain asymptomatic through many years [18].
7.2. Echinococcus multilocularis
The most common presenting complaints include malaise, weight loss, and right upper
quadrant discomfort due to hepatomegaly. Cholestatic jaundice, cholangitis, portal hyperten‐
sion, and the Budd-Chiari syndrome can also occur. The clinical presentation may mimic that
of hepatocellular carcinoma [18].
Extrahepatic primary disease is very rare (1% of cases). Multiorgan disease was described in
13% of cases in one series in which metacestodes involved the lungs, spleen, or brain in addition
to the liver [2]. If left untreated, more than 90% of patients will die within 10 years of the onset
of clinical symptoms, and virtually 100% will die by 15 years [18].
7.3. Echinococcus oligarthus and Echinococcus vogeli
These species cause polycystic echinococcosis, but they represent a very rare cause of echino‐
coccosis disease, found in muscles and skin but it has been only described in a few cases in
Brazil, Venezuela, and Surinam [16, 18, 28, 29].
8. Diagnosis
For an optimal diagnosis, both imaging and serological tests are required.
8.1. Imaging
The cysts may be visualized by ultrasonography, computed tomography (CT), or magnetic
resonance imaging (MRI). However ultrasonography is the most commonly employed
technique due to its easy performance and low cost. The sensitivity of ultrasonography for the
evaluation of echinococcosis is 90% to 95% and the appearance of a cyst in the ultrasound is
as an anechoic and smooth cyst. Another important aspect of the ultrasonography is that it
helps in the classification of the disease, according to the WHO echinococcosis classification
based on their ultrasound appearance. CT has an overall sensitivity of 95% to 100% and is the
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preferred imaging test to describe the size, location, and number of cysts. MRI has the same
sensitivity as that of CT and has no major advantages over CT, but it is better for the determi‐
nation of intra- and extra-hepatic changes; however, it is not usually a routine examination
technique in the patients [18, 27].
8.2. Serological tests
They are used in the diagnosis and follow-up of the patients. Some of the laboratory tests
include complement fixation, latex agglutination, and indirect immunofluorescence [27, 84].
However, there are two important antigens of the E. granulosus disease [18]:
• Antigen 5 which is a parasite antigen; however, the studies have shown low specificity of
its extensive use in the diagnosis [18].
• Antigen B is a lipoprotein and is related with a superior specificity in comparison with the
antigen 5 [18].
8.3. Other laboratory tests for diagnosis
Nonspecific leukopenia or thrombocytopenia, mild eosinophilia, and nonspecific liver
function may be detected but are not diagnostic. Hypergammaglobulinemia and elevated
serum IgE levels are present in more than 50% of cases.
Imaging: On ultrasonography or CT, the lesions usually have an irregular contour with no
well-defined wall, central necrosis, and irregular intralesional and wall calcifications.
8.4. Comparing serologies
Serologic tests are more reliable for diagnosis of E. multilocularis infection than for E. granulo‐
sus infection; sensitivity and specificity rates are 95% to 100%. A specific E. multilocularis
antigen such as the affinity purified Em2 antigen from alveolar echinococcosis metacestodes
is often used; the Em2-ELISA can discriminate between E. granulosus and E. multilocularis in
95% of cases. Serology usually remains positive indefinitely; following complete surgical
resection, serology may normalize within a few years [18].
Cyst aspiration or biopsy: In the absence of a positive serologic test, percutaneous aspiration
or biopsy may be required to confirm the diagnosis by demonstrating the presence of proto‐
scolices, hooklets, or hydatid membranes.
Polymerase chain reaction: Polymerase chain reaction techniques are limited to research
settings but may play a diagnostic role in the future. DNA probes using Southern hybridization
tests are also being developed.
9. Treatment
Echinococcosis treatment includes a multidisciplinary conduct and a general overview of the
patient condition in order to provide the best management that includes surgical treatment,
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pharmacological treatment, the “watch and wait,” and both of them, depending on the specific
characteristics of the disease and most importantly the type of Echinococcosis that the patient
develops. The overall approach depends on the different species that infect humans, particu‐
larly two of them: E. granulosus and E. multilocularis, causing cystic echinococcosis (CE) and
alveolar echinococcosis (AE), respectively [85].
9.1. Cystic echinococcosis
As mentioned earlier, the treatment is complex, and even these days there are no clinical trials
and studies that compare the different modalities to say which one is superior to the other.
However, it is accepted that the surgical treatment can potentially remove all the E. granulo‐
sus cysts for complete cure [30]. The different treatment strategies include surgery, percuta‐
neous management, pharmacological management, and observation [31].
Overall, the diagnosis approach depends on the WHO diagnostic classification, performed in
2003, when the Informal Working Group on echinococcosis established a standardized
ultrasound classification based on the status of the cyst by its ultrasound appearance. This
classification has the intention to promote uniform standards of diagnosis and treatment, and
has important implications for the clinical decision.
There are three different stages, including CE1 and CE2 that are cyst-containing protoscolices.
The CE3 stage is divided in CE3a, a detached endocyst, and CE3b, a solid cyst with daughter
cysts [32]. Recommendations indicate that CE1 and CE3a stages, in which the cyst size is less
than 5 cm, should be treated with albendazole only. Stages CE1 and CE3a with cyst size more
than 5 cm may be treated with albendazole in combination with percutaneous treatment via
PAIR (puncture, aspiration, injection, and reaspiration). The CE2 and CE3b stages are charac‐
terized by multiple cyst compartments that require individual puncture, and these patients
usually require PAIR. However, the optimal choice among the different approaches (PAIR,
surgery, or drug therapy) is uncertain. Finally, stages CE4 and CE5 involve inactive cysts that
only require observation [33, 34].
9.2. Treatment options
9.2.1. Surgery
It is the first treatment option in cases of complicated cysts, including a cyst rupture or infection
and hemorrhage. It is also an alternative treatment option for those cysts with many daughter
vesicles that are not suitable for percutaneous treatment. Another indications are large liver
cysts, cyst diameter more than 10cm, extrahepatic disease (lung, bone, or brain), cysts situated
superficially with high risk of rupture, and cysts affecting the biliary tree [31, 35]. Contrain‐
dications are relative to each patient; for example, old-aged people, people suffering from
concomitant diseases, pregnant women, or patients with small cysts [7]. As far as the compli‐
cations are concerned, secondary infection, intra-abdominal abscess, fistula, or sclerosing
cholangitis have been reported. Recurrent echinococcosis may occur in e 2% to 25% of the cases,
depending basically on the surgeon’s experience [35].
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Before choosing the surgical technique, it's important to administrate drug therapy to mini‐
mize the surgical risk of secondary echinococcosis from seeding of protoscolices in the
abdominal cavity. Usually, albendazole is administered a week before surgery, and continued
at least four weeks after the surgery. Praziquantel is another option, but there is no specific
evidence regarding its efficacy [31, 36].
Surgical approach must be individualized, depending on each patient disease and its charac‐
teristics. There are two options; the first one is to remove the intact cyst, and another option is
to open the cyst with protoscolicidal agents, such as hypertonic saline, followed by the
evacuation of the cyst contents and removal of the cyst [31]. Other protoscolicidal used includes
70% to 95% ethanol and 0.5% cetrimide solution. The protoscolicidal agent must be in contact
with the germinal layer for at least 15 minutes to make its effect. Albendazole, ivermectin, and
praziquantel have been also used as protoscolicidal agents, but their efficacy and safety need
more studies. Protoscolicidal agents should not be used in the presence of biliary communi‐
cation, because of the risk of sclerosing cholangitis or pancreatitis [31, 35].
There is also the possibility of laparoscopic surgery for the treatment of echinococcosis;
however, there are no randomized trials done yet comparing the efficacy of laparoscopy with
open procedures. Possible indications for laparoscopic treatment are the presence of anteriorly
located hepatic cysts, although this procedure is related with associated risk of spillage because
of the elevation of intra-abdominal pressures due to the pneumoperitoneum. Contraindica‐
tions include deep intraparenchymal cysts, the presence of calcified walls cyst, and cysts
located next to the vena cava [31].
In a review article published in 2014 with the aim to study the world literature of the laparo‐
scopic treatment of liver hydatid cyst, a total of 914 patients were identified to evaluate the
mortality, morbidity, and clinical outcomes of the laparoscopic treatment. It was found that
the most common procedure was cystectomy in 60.39% of patients, followed by partial
pericystectomy with 14.77% of patients, and finally pericystectomy with 8.21% of patients, and
the rest of them were treated via segmentectomy. They also reported that conversion of
laparoscopy to open laparotomy occurred in the 4.92% of the cases, due to anatomical
limitations and inaccessible locations. Mortality was reported in 0.22% of the patients and
morbidity was reported in 15.07% of the patients. There was no intraoperative deaths reported
and the most reported complication was bile leakage. In general terms, they concluded that
the laparoscopic procedure is safe, with acceptable ranges of mortality and morbidity and
clinical outcomes comparable to open surgery [37].
9.2.2. Percutaneous management
There are two percutaneous techniques. The first one called PAIR (puncture, aspiration,
injection of a protoscolicidal agent, and reaspiration) is usually effective in the treatment of
cysts without daughter cysts. And the second one, that involves the evacuation of the cyst with
a large bore catheter. This technique helps in cases in which the drain becomes difficult or
tends to relapse after PAIR, like in the case of WHO stages CE2 and CE3b cysts [31, 38].
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Percutaneous treatment is associated with anaphylaxis, happening according to a review in
the 1.6% of the patients [39]. And as in surgery, albendazole must be administered for at least
one month after the percutaneous treatment [31].
9.2.3. PAIR procedure
It was first introduced in the mid-1980s and includes the realization of percutaneous puncture
of the cyst by ultrasonic guidance, aspiration of the cyst fluid, injection of a protoscolicidal
substance, and finally reaspiration of the cyst fluid. PAIR has the advantages of being less
invasive than surgery and can be a diagnostic and therapeutic procedure and it has a success
rate of more than 95%. This procedure may be used in cases of echinococcosis of WHO stages
CE1 and CE3a as primary treatment and for the relapse after medical therapy in stages CE1
and CE3a, and in case of relapse after surgery. PAIR also showed to be successful in the
management of liver cysts and in those cysts located in other abdominal parts such as kidney,
spleen, and in the abdominal cavity. There are controversies in the use of PAIR in pregnant
women and in children, although the application of PAIR is indicated in symptomatic pregnant
women [16, 31, 38].
The procedure is performed by ultrasound or by CT guidance. Then the cyst is punctured and
the fluid aspiration is realized and a histopathological study must be done to evaluate the
presence of protoscolices. After the administration of protoscolicidal agent, the reaspiration
must be done for at least 10 to 15 minutes. Four hours before PAIR, adjunctive drug therapy
with albendazole or mebendazole should be administrated. Recommendations indicate that
albendazole should be continued after a month of the procedure and mebendazole should be
continued for three months. The most important contraindications of the PAIR are the
following: the presence of cysts without drainable solid material, superficial cyst with risk of
rupture in the abdominal cavity, calcified cysts, and cyst with biliary communication [31, 40].
9.2.4. Drug therapy
In most of the cases, it is useful as an adjunctive therapy to surgery and percutaneous treatment.
The use of pharmacological approach as definitive management is indicated in few cases. The
recommendations indicate that in cases of small cysts of WHO stages CE1 and CE3a with cyst
size less than 5 cm, the initial management with only drug therapy is appropriate, with optimal
duration of treatment depending on the clinical factors, but usually estimated in around one
to six months. The effectiveness of pharmacological therapy decreases with the presence of a
cyst size more than 5 cm, with multiple compartments of cysts [16, 31, 39].
As an adjunctive treatment, albendazole is used as perioperative drug therapy in surgery or
in percutaneous treatment. It reduces the risk of recurrent disease by the inactivation of the
protoscolices. There is no general consensus of the duration of the treatment, but generally it
is initiated four days before surgery and continued at least one month after the surgery in case
of albendazole and for three months in case of mebendazole [16, 31, 40, 42].
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Albendazole is the first drug option and the primary antiparasitic agent for treatment of E.
granulosus, and in cases of absence of albendazole, mebendazole may be used as an alternative,
but it is less absorbed than albendazole. The primary action of albendazole is that it inhibits
microtubules assembly, causing a glycogen depletion, followed by the degeneration of the
mitochondria and the endoplasmic reticulum, finally causing the cell death. It is reported that
albendazole helps cyst resolution in 30% of the patients, cyst size reduction in 30% to 50%
patients, and in 20% to 40% of the patients, there are no changes in the cysts. However, the
outcome of the treatment with albendazole depends on multiple factors like the clinical
characteristic of the patient, the cyst size, and its location [31, 43].
However, albendazole has more advantages than mebendazole. For example, albendazole is
well tolerated by patients and it takes a shorter duration of therapy. Dose of albendazole is
usually 10 to 15 mg/kg per day divided in two doses and mebendazole dose is 40 to 50 mg/kg
per day divided in three doses. Adverse effects include hepatotoxicity in 1% to 5% of the
patients, cytopenia, and alopecia in less than 1% of the patients. Due to hepatotoxicity, there
might be an increase in aminotransferase enzymes. Other rare side effect like agranulocytosis
has also been reported. Contraindications of using albendazole include patients with liver
disease or bone marrow suppression [31, 44]. Patients with pharmacological therapy must be
monitored every two to three weeks for first three months and then monthly [31]. Praziquantel
has protoscolicidal activity, but its efficacy in clinical studies is variable, but is considered as
an alternative when the albendazole treatment cannot be administrated [44, 45].
Observation: Also known as the “watch and wait,” indicated in the WHO stages CE4 and CE5,
in patients with absence of complications or inactive liver cysts [40].
9.3. Alverolar echinococcosis
Unfortunately, the treatment of alveolar echinococcosis is less effective than the treatment of
cystic echinococcosis. The general approach to the treatment is based on surgery. The main
idea is to remove all the infected tissue and sometimes it is necessary to also remove part of
the host tissue. Management with albendazole is recommended after surgery with an uncertain
optimal duration. The benefit of preoperative albendazole administration has not been
reported [31].
10. Conclusions
Echinococcosis has always been neglected worldwide and especially in Colombia. Particularly
in this country, research was done and published only between 1950s and 1990s. There is no
subsequent interest in the occurrence of this disease and all its implications.
Due to the impact of echinococcosis, the burden it creates, and the consequences in the patients,
it becomes important to create strategies in order to improve and have a better control on this
disease in our country. This probably should begin at medical schools, where more emphasis
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on teaching about this parasitic disease, would increase awareness about it. As has been
mentioned earlier, there should be regular interaction among physicians, biologists and
veterinarians to better understand the implications of this zoonotic disease, which at least from
an enzootic point of view is clearly extended. As an additional reflection in the middle of the
process and discussion about peace in Colombia, there are chances that once this would be
reached, after the La Habana discussions, more people, not only missionary, health, and
military corps, would be allowed to enter in the guerrillas-controlled areas, which are precisely
located where enzootic evidences of echinococcosis have been reported, increasing the
exposure to species of Echinococcus and probably making more visible the occurrence of this
disease in the country [78].
Even more, it’s not clear yet, if Colombia would be considered properly a risky area for
travelers visiting the country in the view of acquisition of echinococcosis. But certainly in other
highly endemic countries, echinococcosis is included in the list of infectious diseases that can
be acquired during travel, and cases of echinococcosis, as well from other cestodiasis, have
been reported increasingly during the last few years [75-78].
Therefore, it becomes crucial to create a clear and easy consensus to help and guide the
physicians to make a better approach towards helping the patients in finding the opportune
diagnosis and the best treatment option. The creation of a normative and the global vision of
echinococcosis as a public health problem might help improve the control of this disease.
Echinococcosis, and other zoonotic diseases, can re-emerge just when they are considered to
be under control or eliminated. They can go into hiding in the animal reservoirs, so there is no
possibility for complacency [78]. Epidemiology of zoonoses such as echinococcosis is complex
and dynamic, being influenced by varying parameters that can roughly be categorized as
human-related, pathogen-related, and climate/environment-related [79, 80]. But certainly for
echinococcosis, there is still much to understand.
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